Short Interest in iBio, Inc. (NASDAQ:IBIO) Rises By 100.6%

iBio, Inc. (NASDAQ:IBIO) was the recipient of a significant growth in short interest during the month of December. As of December 15th, there was short interest totaling 3,906,126 shares, a growth of 100.6% from the November 30th total of 1,947,486 shares. Based on an average daily volume of 22,914,016 shares, the days-to-cover ratio is currently 0.2 days. Currently, 17.9% of the company’s shares are short sold. Currently, 17.9% of the company’s shares are short sold. Based on an average daily volume of 22,914,016 shares, the days-to-cover ratio is currently 0.2 days.

Analyst Ratings Changes

Several research analysts recently commented on IBIO shares. Lifesci Capital raised shares of iBio to a “strong-buy” rating in a research note on Thursday, December 18th. Wall Street Zen raised shares of iBio from a “strong sell” rating to a “hold” rating in a report on Sunday, November 16th. Leerink Partnrs raised shares of iBio to a “strong-buy” rating in a research note on Friday, October 17th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of iBio in a report on Monday, December 22nd. Two investment analysts have rated the stock with a Strong Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Buy”.

iBio Price Performance

iBio stock traded up $0.02 during mid-day trading on Friday, reaching $1.89. 891,405 shares of the company traded hands, compared to its average volume of 13,432,008. iBio has a 52-week low of $0.56 and a 52-week high of $6.89. The stock has a market capitalization of $42.50 million, a price-to-earnings ratio of -1.36 and a beta of 1.13. The stock’s 50 day moving average price is $1.48.

iBio (NASDAQ:IBIO) last announced its earnings results on Wednesday, November 12th. The company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.04). The firm had revenue of $0.10 million for the quarter.

About iBio

iBio, Inc, a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever.